[go: up one dir, main page]

MX2021014245A - Procedimientos y productos intermedios para preparar un inhibidor de btk. - Google Patents

Procedimientos y productos intermedios para preparar un inhibidor de btk.

Info

Publication number
MX2021014245A
MX2021014245A MX2021014245A MX2021014245A MX2021014245A MX 2021014245 A MX2021014245 A MX 2021014245A MX 2021014245 A MX2021014245 A MX 2021014245A MX 2021014245 A MX2021014245 A MX 2021014245A MX 2021014245 A MX2021014245 A MX 2021014245A
Authority
MX
Mexico
Prior art keywords
preparing
btk inhibitor
intermediates
procedures
preparation
Prior art date
Application number
MX2021014245A
Other languages
English (en)
Inventor
Andras Horvath
Laurent Lefort
Philip James Pye
Bernardus Kaptein
Gerardus Karel Maria Verzijl
Yuanyuan Yuan
Jinxiong Su
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2021014245A publication Critical patent/MX2021014245A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/02—Preparation by ring-closure or hydrogenation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/98—Nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se da a conocer un procedimiento para la preparación de determinados productos intermedios, por ejemplo, procedimiento para preparar un compuesto de fórmula (I) (ver Fórmula) o una sal farmacéuticamente aceptable del mismo, en una forma enantioenriquecida, cuyo producto intermedio y procedimientos son útiles en la preparación de un inhibidor de BTK, tal como ibrutinib.
MX2021014245A 2019-05-21 2020-05-20 Procedimientos y productos intermedios para preparar un inhibidor de btk. MX2021014245A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019087804 2019-05-21
PCT/EP2020/064119 WO2020234379A1 (en) 2019-05-21 2020-05-20 Processes and intermediates for preparing a btk inhibitor

Publications (1)

Publication Number Publication Date
MX2021014245A true MX2021014245A (es) 2022-01-06

Family

ID=70857159

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014245A MX2021014245A (es) 2019-05-21 2020-05-20 Procedimientos y productos intermedios para preparar un inhibidor de btk.

Country Status (11)

Country Link
US (1) US20220235058A1 (es)
EP (1) EP3972956A1 (es)
JP (1) JP2022533219A (es)
KR (1) KR20220011669A (es)
CN (2) CN120136774A (es)
AU (1) AU2020280904A1 (es)
BR (1) BR112021022646A2 (es)
CA (1) CA3135211A1 (es)
IL (1) IL288155A (es)
MX (1) MX2021014245A (es)
WO (1) WO2020234379A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ575650A (en) 2006-09-22 2011-10-28 Pharmacyclics Inc Pyrimidinopyrazole derivatives as inhibitors of Bruton's tyrosine kinase
RS53167B (en) 2009-03-31 2014-06-30 Boehringer Ingelheim International Gmbh 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO [3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR APPLICATIONS AS A PDE9A MODULATOR
KR101668574B1 (ko) * 2012-11-02 2016-10-24 화이자 인코포레이티드 브루톤 티로신 키나제 억제제
BR112015021856A2 (pt) 2013-03-15 2017-07-18 Janssen Pharmaceutica Nv processos e intermediários para a preparação de um medicamento
CN103626774B (zh) * 2013-11-20 2015-11-04 苏州明锐医药科技有限公司 伊鲁替尼的制备方法
CN106795124A (zh) * 2014-10-30 2017-05-31 桑多斯股份公司 取代的1H‑吡唑并[3,4‑d]嘧啶类化合物的合成
MA41350A (fr) 2015-01-14 2017-11-21 Janssen Pharmaceutica Nv Synthèse d'un inhibiteur de la tyrosine kinase de bruton
CN107233344B (zh) * 2017-07-20 2021-03-02 河南师范大学 一种抗肿瘤药物依鲁替尼的制备方法
CN107385966A (zh) * 2017-07-20 2017-11-24 毛龙飞 一种新型有机硅类皮革染色助剂及其制备方法
CN107383017B (zh) * 2017-07-20 2020-01-14 河南师范大学 依鲁替尼高效制备方法
CN109180683A (zh) * 2018-09-07 2019-01-11 南通雅本化学有限公司 一种依鲁替尼的制备方法

Also Published As

Publication number Publication date
CN113906011B (zh) 2025-05-13
US20220235058A1 (en) 2022-07-28
JP2022533219A (ja) 2022-07-21
CN113906011A (zh) 2022-01-07
AU2020280904A1 (en) 2021-11-18
IL288155A (en) 2022-01-01
WO2020234379A1 (en) 2020-11-26
CN120136774A (zh) 2025-06-13
BR112021022646A2 (pt) 2022-03-29
EP3972956A1 (en) 2022-03-30
CA3135211A1 (en) 2020-11-26
KR20220011669A (ko) 2022-01-28

Similar Documents

Publication Publication Date Title
CO2019011809A2 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CL2019002204A1 (es) Compuestos inhibidores del vih.
CL2021000783A1 (es) Proceso de fabricación de un compuesto para la inhibición de la actividad de shp2
UY37927A (es) Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
MX2019010541A (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
CO2022002637A2 (es) Proceso de fabricación de moduladores de cftr
CY1120080T1 (el) Φαρμακευτικη συνθεση περιεχουσα εναν αναστολεα hdac και εναν κυκλοπολυσακχαριτη
CU20200053A7 (es) Compuesto de pirimidina como inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación
MX2015012731A (es) Procesos e intermedios para preparar un medicamento.
EA202193015A1 (ru) Ингибиторы cdk
BR112017019287A2 (pt) composto, composição farmaceuticamente aceitável, método de tratamento de câncer, processo para preparar o composto da fórmula i, método para tratar câncer, e kit
EA201792116A1 (ru) Ингибитор янус-киназы
CR20140052A (es) Un derivado novedoso de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes
MX2018008966A (es) Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo.
MX2019014054A (es) Profarmacos de glucuronida de inhibidores de la cinasa janus.
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
SG10201902609TA (en) Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same
MX2017001459A (es) Sintesis de fosforamidatos.
PH12021550883A1 (en) Crystalline salts of a plasma kallikrein inhibitor
AR086987A1 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
CO2022002392A2 (es) Síntesis de un inhibidor de calicreína plasmática a escala de proceso
AR126196A1 (es) Proceso para preparar inhibidores de egfr
MX391856B (es) Compuesto de pirrolopiridina novedoso, metodo de preparacion del mismo y uso del mismo
MX2021014245A (es) Procedimientos y productos intermedios para preparar un inhibidor de btk.